Needham & Company LLC reaffirmed their buy rating on shares of Surmodics (NASDAQ:SRDX - Free Report) in a research note published on Wednesday, Benzinga reports. Needham & Company LLC currently has a $47.00 price objective on the stock.
Separately, StockNews.com upgraded Surmodics from a hold rating to a buy rating in a report on Thursday, December 14th.
View Our Latest Stock Report on Surmodics
Surmodics Stock Down 0.4 %
Shares of NASDAQ:SRDX traded down $0.11 during midday trading on Wednesday, hitting $27.64. 53,666 shares of the stock were exchanged, compared to its average volume of 45,497. The company has a debt-to-equity ratio of 0.24, a quick ratio of 3.97 and a current ratio of 4.84. Surmodics has a 52-week low of $16.79 and a 52-week high of $39.41. The business's fifty day simple moving average is $30.10 and its two-hundred day simple moving average is $32.09. The company has a market capitalization of $393.59 million, a PE ratio of 72.74 and a beta of 1.01.
Institutional Investors Weigh In On Surmodics
Institutional investors have recently added to or reduced their stakes in the stock. Tower Research Capital LLC TRC raised its position in Surmodics by 305.8% in the 3rd quarter. Tower Research Capital LLC TRC now owns 775 shares of the company's stock worth $25,000 after purchasing an additional 584 shares during the last quarter. UBS Group AG raised its position in Surmodics by 141.1% in the 3rd quarter. UBS Group AG now owns 2,290 shares of the company's stock worth $70,000 after purchasing an additional 1,340 shares during the last quarter. Teachers Retirement System of The State of Kentucky bought a new position in Surmodics in the 3rd quarter worth approximately $87,000. Captrust Financial Advisors raised its position in Surmodics by 24.3% in the 1st quarter. Captrust Financial Advisors now owns 2,307 shares of the company's stock worth $105,000 after purchasing an additional 451 shares during the last quarter. Finally, Citigroup Inc. raised its position in Surmodics by 1,023.0% in the 2nd quarter. Citigroup Inc. now owns 4,144 shares of the company's stock worth $130,000 after purchasing an additional 3,775 shares during the last quarter. 96.63% of the stock is owned by institutional investors and hedge funds.
Surmodics Company Profile
(
Get Free Report)
Surmodics, Inc, together with its subsidiaries, provides performance coating technologies for intravascular medical devices, and chemical and biological components for in vitro diagnostic immunoassay tests and microarrays in the United States and internationally. It operates through two segments, Medical Device and In Vitro Diagnostics (IVD).
See Also
Before you consider Surmodics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Surmodics wasn't on the list.
While Surmodics currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Do you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.
Get This Free Report
